Clinical Trials Logo

Neovascularization, Pathologic clinical trials

View clinical trials related to Neovascularization, Pathologic.

Filter by:

NCT ID: NCT00559936 Completed - Clinical trials for Corneal Neovascularization

Topical Avastin for Treatment of Corneal Neovascularization

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.

NCT ID: NCT00556348 Completed - Clinical trials for Age Related Macular Degeneration

Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

Start date: November 2005
Phase: Phase 4
Study type: Interventional

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular degeneration.

NCT ID: NCT00555594 Completed - Clinical trials for Corneal Neovascularization

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Start date: September 2006
Phase: Phase 2/Phase 3
Study type: Interventional

To determine the effect of subconjunctival Bevacizumab in corneal neovascularization

NCT ID: NCT00533520 Completed - Clinical trials for Macular Degeneration

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

BGB/IST
Start date: September 2007
Phase: Phase 4
Study type: Interventional

Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).

NCT ID: NCT00512876 Completed - Clinical trials for Corneal Neovascularization

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Start date: August 2007
Phase: N/A
Study type: Interventional

Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.

NCT ID: NCT00511706 Completed - Clinical trials for Choroidal Neovascularization

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Start date: November 1, 2007
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

NCT ID: NCT00510965 Completed - Clinical trials for Choroidal Neovascularization

Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in the treatment of choroidal neovascularization in underlying angioid streaks due to Pseudoxanthoma elasticum. 10 patients will receive monthly injections of the drug in one eye over a period of one year.

NCT ID: NCT00509704 Completed - Renal Cell Cancer Clinical Trials

Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma

Start date: October 2008
Phase: N/A
Study type: Observational

The purpose of the study is to assess the effect of Sunitinib on tumor vascularization and necrosis in patients with metastatic renal cell cancer.

NCT ID: NCT00504959 Completed - Clinical trials for Subfoveal Choroidal Neovascularization (CNV)

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Start date: July 2007
Phase: Phase 4
Study type: Interventional

This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN

NCT ID: NCT00500344 Completed - Clinical trials for Age-related Macular Degeneration

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

CAPTAIN
Start date: July 2007
Phase: Phase 1
Study type: Interventional

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD